Sana Biotechnology, Inc.

Healthcare · Biotechnology · United States

Last price 2.57 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 769.36M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company’s product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therap...